ISRCTN13284995进行中（未招募）1 期
Phase I trial, IQVIA Biotech code: Breye-C22-1005 [The full scientific title will be published within 30 months after the end of the trial]
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
进行中（未招募）
1 期
Phase I trial, HMR code: 22-016Healthy volunteersISRCTN17231793xera Pharma UK Ltd104
进行中（未招募）
1 期
Phase I trial: QSC206159Healthy volunteersISRCTN51392723Oxilio Limited12
已完成
Unknown
Phase 1 trial: CA38951Healthy volunteersISRCTN46343886Millicent Pharma Limited36
招募中
1 期
64Cu-NCAB001 in patients with pancreatic cancerPancreatic cancer without clinically distant metastasisC535836Pancreatic cancerJPRN-jRCT2031230311Hijioka Susumu18